GoodRx (GDRX) Expected to Announce Quarterly Earnings on Wednesday

GoodRx (NASDAQ:GDRX) is expected to announce its Q4 2025 results after the market closes on Wednesday, February 25th. Analysts expect the company to announce earnings of $0.09 per share and revenue of $193.2670 million for the quarter. Individuals can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, February 26, 2026 at 8:00 AM ET.

GoodRx Stock Up 4.7%

NASDAQ:GDRX opened at $2.47 on Monday. The company has a current ratio of 3.11, a quick ratio of 3.11 and a debt-to-equity ratio of 0.81. GoodRx has a twelve month low of $2.10 and a twelve month high of $5.81. The company has a market cap of $838.39 million, a PE ratio of 27.44, a P/E/G ratio of 0.94 and a beta of 1.50. The company’s 50 day moving average is $2.56 and its two-hundred day moving average is $3.31.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on GDRX. Citigroup dropped their price objective on shares of GoodRx from $5.00 to $4.50 and set a “buy” rating on the stock in a report on Friday, January 9th. TD Cowen dropped their price target on GoodRx from $7.00 to $6.00 and set a “buy” rating on the stock in a research note on Monday, November 10th. JPMorgan Chase & Co. cut their price objective on GoodRx from $6.00 to $5.00 and set an “overweight” rating on the stock in a report on Tuesday, November 11th. Mizuho decreased their target price on GoodRx from $5.00 to $4.00 and set a “neutral” rating for the company in a report on Thursday, November 6th. Finally, UBS Group dropped their target price on GoodRx from $4.25 to $4.00 and set a “neutral” rating on the stock in a research report on Thursday, November 6th. Five equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and three have assigned a Sell rating to the company’s stock. According to MarketBeat.com, GoodRx presently has a consensus rating of “Hold” and an average price target of $4.73.

Institutional Trading of GoodRx

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Quarry LP purchased a new position in GoodRx during the third quarter valued at approximately $33,000. MML Investors Services LLC acquired a new position in shares of GoodRx in the 4th quarter valued at $36,000. DRW Securities LLC purchased a new stake in GoodRx during the fourth quarter worth $40,000. Boothbay Fund Management LLC acquired a new stake in GoodRx during the third quarter valued at $43,000. Finally, EP Wealth Advisors LLC acquired a new stake in GoodRx during the fourth quarter valued at $44,000. 63.77% of the stock is owned by institutional investors and hedge funds.

GoodRx Company Profile

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.